Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The lack of immunocompetent small animal models for hepatitis C virus (HCV) has greatly hindered the development of effective vaccines. Using rodent hepacivirus (RHV), a homologue of HCV that shares many characteristics of HCV infection, we report the development and application of a novel RHV/ outbred rat model for HCV vaccine development. Simian adenovirus (ChAdOx1) encoding a genetic immune enhancer (truncated shark class II invariant chain) fused to the non-structural proteins NS3-NS5B from RHV (ChAd-NS) was used to vaccinate Sprague-Dawley rats, resulting in high levels of CD8+ T-cell responses. Following RHV challenge (using 10x or 100x the minimum infectious dose), 42% of vaccinated rats cleared infection within 6-8 weeks, while all mock vaccinated controls became infected with high level viraemia post-challenge. A single, 7-fold higher dose of ChAd-NS increased efficacy to 67%. Boosting with ChAd-NS, or with a plasmid encoding the same NS3-NS5B antigens, increased efficacy to 100% and 83% respectively. A ChAdOx1 vector encoding structural antigens (ChAd-S) was also constructed. ChAd-S alone showed no efficacy. Strikingly, when combined with ChAd-NS, ChAD-S produced 83% efficacy. Protection was associated with a strong CD8+ IFNγ+ recall response against NS4. Next-generation sequencing of a putative RHV escape mutant in a vaccinated rat identified mutations in both of two identified immunodominant CD8+ T-cell epitopes. CONCLUSIONS: A simian adenovirus vector vaccine strategy is effective at inducing complete protective immunity in the rat/RHV model. The RHV SD rat challenge model enables comparative testing of vaccine platforms and antigens, identification of correlates of protection and thereby provides a small animal experimental framework to guide the development of an effective vaccine for HCV in humans. This article is protected by copyright. All rights reserved.

Original publication

DOI

10.1002/hep.30894

Type

Journal article

Journal

Hepatology (Baltimore, Md.)

Publication Date

10/08/2019

Addresses

Peter Medawar Building for Pathogen Research, University of Oxford, UK.